nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Side Effects"

 

FDA Resource for Dietary Supplements
July 11, 2022   

The U.S. Food and Drug Administration has released a resource for consumers to provide education for dietary supplements. Despite limited evidence about the efficacy and safety of dietary supplements for improving mental health, people with or without mental disorders often tend to use them. ...
 Continue reading (Members only)
Screening for Tardive Dyskinesia
June 29, 2022   

The American Academy of Neurology (AAN) has released updated recommendations for treatment of tardive syndromes...
 Continue reading
2021 NEI Congress Taking a Bite Out of Nutrition and Mental Health
November 7, 2021   

During the 2021 NEI Congress, Dr. Andrew Cutler presented a fascinating lecture on the influence of nutrition on mental health. He presented metabolic contributors to mental illness, along with an examination of the role that inflammation, and specific diets play in mental health. Possible contributors to mental illness are..
 Continue reading
Insulin Resistance Linked to Major Depressive Disorder
October 7, 2021   

Major depressive disorder is often difficult to predict yet is the leading cause of disability worldwide. A growing body of literature suggests that metabolic parameters may influence the development or worsening of depression. In this longitudinal study of nearly...
 Continue reading (Members only)
Do Psychiatric Disorders Present With Distinct or Shared Gut Microbial Alterations?
October 4, 2021   

Several lines of evidence suggest an involvement of the gut microbiota in the pathophysiology of psychiatric disorders, albeit with contradictory results. A review and meta-analysis of studies examining alpha and beta diversity and relative abundance of gut microbes in adult psychiatric populations...
 Continue reading
FDA Approves a New Atypical Antipsychotic With Less Adverse Effects
June 2, 2021   

The US Food and Drug Administration announced their approval of Alkermes’ combination of olanzapine and samidorphan, for the treatment of adults with schizophrenia and/or bipolar I disorder...
 Continue reading
Long-Acting Injectable Antipsychotics Cut Suicide Death Risk in Half
June 1, 2021   

In a recent population-based cohort study of patients with schizophrenia who received oral antipsychotics (OAPs), data from the Taiwan National Health Insurance Research Database was analyzed. Within this cohort, the study examined risk of suicide in those patients who switched to long-acting injectable antipsychotics compared to those who remained on OAPs...
 Continue reading (Members only)
Switching Antipsychotics to Ameliorate Weight Gain
February 23, 2021   

Atypical antipsychotics are often associated with detrimental metabolic changes that may influence treatment adherence, quality of life, and mortality. In this meta-analysis, the authors investigated the benefits of switching from one antipsychotic to another with less propensity for metabolic changes...
 Continue reading
Top of Page